Latest News and Press Releases

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated...

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and...

Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing

Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with CRSwNP

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at EACCI 2025

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio CEO to participate in fireside chat at Piper Sandler